Drug Trial Radar · NCT02757768
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
715
Actual
Start
Jun 13, 2016
Primary completion
Aug 14, 2018
Study completion Sep 11, 2018
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
Conditions
- Benign Prostatic Hyperplasia
- Overactive Bladder
Interventions
MirabegronDrug
Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
PlaceboDrug
Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Tamsulosin HydrochlorideDrug
Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per DayTime frame: Baseline and Week 12
Locations
79 sites in 9 countries. Site status is shown where the registry gives one.
Site US01009
Homewood, Alabama
Site US01005
Huntsville, Alabama
Site US01012
Anchorage, Alaska
Site US01070
Hawaiian Gardens, California
Site US01081
Los Angeles, California
Site US01021
Murrieta, California
Site US01068
San Diego, California
Site US01064
Valley Village, California
Site US01097
Englewood, Colorado
Site US01026
Pompano Beach, Florida
Site US01025
St. Petersburg, Florida
Site US01027
Wellington, Florida
Site US01034
West Des Moines, Iowa
Site US01094
Shreveport, Louisiana
Site US01041
Baltimore, Maryland
Site US01016
Boston, Massachusetts
Site US01003
Watertown, Massachusetts
Site US01060
Kansas City, Missouri
Site US01067
Billings, Montana
Site US01061
Omaha, Nebraska
Site US01029
Edison, New Jersey
Site US01031
Albuquerque, New Mexico
Site US01015
Garden City, New York
Site US01019
Plainview, New York
Site US01069
Cary, North Carolina
Site US01079
Maiden, North Carolina
Site US01072
Bristol, Tennessee
Site US01042
Clarksville, Tennessee
Site US01056
Knoxville, Tennessee
Site US01075
Knoxville, Tennessee
Site US01078
Knoxville, Tennessee
Site US01063
Newport News, Virginia
Site CA15008
Calgary, Alberta, Canada
Site CA15003
Barrie, Ontario, Canada
Site CA15001
Brampton, Ontario, Canada
Site CA15005
Toronto, Ontario, Canada
Site CA15011
Québec, Quebec, Canada
Site CA15002
Sherbrooke, Quebec, Canada
Site CA15009
Sherbrooke, Quebec, Canada
Site CA15014
Victoriaville, Quebec, Canada
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.